$0.65
12.46%
Nasdaq, Nov 17, 04:00 pm EST.
ISIN
US88875G1013
Symbol
TLSA

Tiziana Life Sciences PLC Sponsored ADR Stock News

Neutral
●
GlobeNewsWire
●
9 days ago
BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today provided additional context on the positive topline results from its Phase 2a INFORM-MS trial, bui...
Neutral
●
GlobeNewsWire
●
13 days ago
BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced that it will host a conference call and webcast with Key Opinion Leaders (KOLs) to discu...
Positive
●
Reuters
●
16 days ago
Tiziana Life Sciences said on Monday its experimental therapy for a progressive form of ​multiple sclerosis with no approved treatments ‌reduced brain inflammation and showed a favorable safety profile in a mid-stage trial.
Positive
●
Proactive Investors
●
about one month ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient has begun dosing in its Phase 2 trial of intranasal foralumab in early or mild Alzheimer's disease, with topline data expected in the first quarter of 2027.  The milestone completes enrollment and dosing initiation for all participants in the randomized, placebo-controlled study, the biotechnology company said.
Neutral
●
GlobeNewsWire
●
about one month ago
BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the last patient has begun dosing in its Phase 2 randomized, placebo-controlled cl...
Positive
●
Proactive Investors
●
about 2 months ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for multiple system atrophy (MSA), a rare neurodegenerative disease with no approved disease-modifying therapies.  MSA is a rapidly progressive disorder that affects autonomic functions such as blood pressure and bladder control, as well as motor con...
Neutral
●
Proactive Investors
●
about 2 months ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial in people living with amyotrophic lateral sclerosis (ALS).  The Healey ALS MyMatch BANYAN trial is testing foralumab, a fully human anti-CD3 monoclonal antibody, delivered as a nasal spray.
Neutral
●
Proactive Investors
●
about 2 months ago
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The randomized, double-blind, placebo-controlled INFORM-MS trial enrolled 48 patients across three cohorts at multiple leading U.S.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today